Today: 21 May 2026
Oklo stock slides after insider sales disclosures as traders reassess Meta nuclear deal
15 January 2026
2 mins read

Oklo stock slides after insider sales disclosures as traders reassess Meta nuclear deal

NEW YORK, Jan 15, 2026, 15:40 (ET) — Regular session

  • Oklo shares dropped roughly 4% in afternoon trading following executive stock-sale disclosures filed earlier this week
  • Filings reveal that CEO Jacob DeWitte and COO Caroline Cochran offloaded shares through established Rule 10b5-1 trading plans
  • Investors are focused on licensing and funding news related to Oklo’s Ohio project, backed by Meta

Oklo Inc. shares dropped 3.8%, slipping $3.69 to $92.28 on Thursday afternoon. The stock swung between $99.14 and $92.25, with roughly 8.7 million shares changing hands, as investors reacted to insider-sale disclosures and trimmed gains from the recent nuclear power rally.

Timing is crucial. Oklo, a high-volatility stock linked to the hunt for “firm” power solutions for data centers, has attracted momentum investors. In such a volatile setup, insider selling—even when expected—can unsettle shareholders.

Big Tech is making moves into nuclear power. Last week, Meta Platforms announced deals with Vistra and also with Oklo and TerraPower, aiming to secure steady electricity for data centers and AI operations.

Two Form 4 filings submitted on Jan. 13 revealed that Oklo co-founder and CEO Jacob DeWitte, along with co-founder and COO Caroline Cochran, each sold roughly 45,800 Class A shares on Jan. 9. The shares went for weighted average prices between $111.38 and $112.83. According to the forms, these sales fell under Rule 10b5-1 plans put in place on March 31, 2025. Despite offloading shares, both DeWitte and Cochran still control significant holdings, including millions of shares held through family trusts, the documents showed.

On Jan. 9, Oklo announced an agreement with Meta to back a 1.2-gigawatt nuclear campus in Pike County, Ohio. The deal lets Meta prepay for power and bankroll early development work. “Meta’s funding commitment … is a major step,” said DeWitte. Meta’s energy chief, Urvi Parekh, highlighted the pact’s role in supporting local operations, including an AI “supercluster” in New Albany, Ohio. Oklo

Oklo underperformed its nuclear-sector peers on Thursday. Vistra jumped 6.5%, and Constellation Energy climbed roughly 3.1%, but NuScale Power dropped 4.7%.

Broader markets edged higher, but Oklo lagged noticeably. The SPY and QQQ ETFs, tracking the S&P 500 and Nasdaq respectively, posted slight gains.

Rule 10b5-1 plans set up automatic trading instructions, allowing executives to buy or sell shares on a fixed timetable. These plans aim to shield them from claims of trading on insider info. But they don’t prevent strong market moves, especially when many investors are piled into the same trade.

The bigger risk lies in execution and permits. The U.S. Nuclear Regulatory Commission rejected Oklo’s license application for its smaller Aurora design back in 2022, according to a review by the American Nuclear Society this week. Since then, the company has adjusted its planned capacity.

Traders are closely monitoring updates on licensing, fuel supply, and the pace at which the Meta-backed Ohio site progresses from planning to actual construction. A change in the timeline or the addition of another major customer could send shares moving sharply.

The next catalyst is Oklo’s upcoming earnings report, slated for March 23 per Zacks. Investors will probably zero in on cash burn and progress on the Ohio project.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn
Previous Story

Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop